Iron overload in myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 49, Issue 3, 2008, Pages 427-438

  Mahesh, Sameer ^a   Ginzburg, Yelena ^b   Verma, Amit ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

Myeloid leukemias and dysplasias; Pharmacotherapeutics; Prognostication

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; IRON CHELATING AGENT; PLACEBO; TRANSFERRIN;

AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHROPATHY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BETA THALASSEMIA; BLOOD TRANSFUSION; BLURRED VISION; CANCER CLASSIFICATION; CANCER SURVIVAL; CARDIOMYOPATHY; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; FATIGUE; GLUCOSE INTOLERANCE; HEADACHE; HEARING IMPAIRMENT; HEARING LOSS; HEART ARRHYTHMIA; HEMATOPOIESIS; HEMOCHROMATOSIS; HUMAN; HYPERSENSITIVITY REACTION; IMPOTENCE; INTRAOCULAR PRESSURE; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; LEUKOCYTOCLASTIC VASCULITIS; LIVER BIOPSY; LIVER DYSFUNCTION; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; NIGHT BLINDNESS; NIGHT VISION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT MONITORING; PERCEPTION DEAFNESS; PERIPHERAL VISION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RETINA MACULOPATHY; RETINA PIGMENT EPITHELIOPATHY; REVIEW; RHINOPHARYNGITIS; SCOTOMA; SIDE EFFECT; THALASSEMIA; THROMBOCYTOPENIA; TINNITUS; URTICARIA; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD TRANSFUSION; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 39749126765     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701843221     Document Type: Review

References (62)

1. Heaney, M. L. and Golde, D. W. (1999) Myelodysplasia. N Engl J Med, 340, pp. 1649-1660.
2. Steensma, D. P. and Bennett, J. M. (2006) The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc, 81, pp. 104-130.
3. Sperr, W. R., Wimazal, F., Kundi, M., Fonatsch, C., Thalhammer-Scherrer, R. and Schernthaner, G. H. (2001) Survival analysis and AML development in patients with de novo myelodysplastic syndromes: Comparison of six different prognostic scoring systems. Ann Hematol, 80, pp. 272-277.
4. Kerkhofs, H., Hermans, J., Haak, H. L. and Leeksma, C. H. (1987) Utility of the FAB classification for myelodysplastic syndromes: Investigation of prognostic factors in 237 cases. Br J Haematol, 65, pp. 73-81.
5. Nosslinger, T., Reisner, R., Koller, E., Gruner, H., Tuchler, H. and Nowotny, H. (2001) Myelodysplastic syndromes, from French - American - British to World Health Organization: Comparison of classifications on 431 unselected patients from a single institution. Blood, 98, pp. 2935-2941.
6. Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P. and Sanz, G. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, pp. 2079-2088.
7. Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K. and Vardiman, J. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol, 17, pp. 3835-3849.
8. List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A. and Feldman, E. (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med, 355, pp. 1456-1465.
9. Malcovati, L., Porta, M. G., Pascutto, C., Invernizzi, R., Boni, M. and Travaglino, E. (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol, 23, pp. 7594-7603.
10. Park, C. H., Valore, E. V., Waring, A. J. and Ganz, T. (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem, 276, pp. 7806-7810.
11. Nicolas, G., Bennoun, M., Devaux, I., Beaumont, C., Grandchamp, B. and Kahn, A. (2001) Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA, 98, pp. 8780-8785.
12. Nicolas, G., Bennoun, M., Porteu, A., Mativet, S., Beaumont, C. and Grandchamp, B. (2002) Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA, 99, pp. 4596-4601.
13. Donovan, A., Lima, C. A., Pinkus, J. L., Pinkus, G. S., Zon, L. I. and Robine, S. (2005) The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab, 1, pp. 191-200.
14. Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A. and Ward, D. M. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 306, pp. 2090-2093.
15. Knutson, M. D., Oukka, M., Koss, L. M., Aydemir, F. and Wessling-Resnick, M. (2005) Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci USA, 102, pp. 1324-1328.
16. Nemeth, E. and Ganz, T. (2006) Regulation of iron metabolism by hepcidin. Annu Rev Nutr, 26, pp. 323-342.
17. Papanikolaou, G., Tzilianos, M., Christakis, J. I., Bogdanos, D., Tsimirika, K. and MacFarlane, J. (2005) Hepcidin in iron overload disorders. Blood, 105, pp. 4103-4105.
18. Adamsky, K., Weizer, O., Amariglio, N., Breda, L., Harmelin, A. and Rivella, S. (2004) Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol, 124, pp. 123-124.
19. Hershko, C., Graham, G., Bates, G. W. and Rachmilewitz, E. A. (1978) Non-specific serum iron in thalassaemia: An abnormal serum iron fraction of potential toxicity. Br J Haematol, 40, pp. 255-263.
20. Cabantchik, Z. I., Breuer, W., Zanninelli, G. and Cianciulli, P. (2005) LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol, 18, pp. 277-287.
21. Breuer, W., Hershko, C. and Cabantchik, Z. I. (2000) The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci, 23, pp. 185-192.
22. Esposito, B. P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C. and Cabantchik, Z. I. (2003) Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood, 102, pp. 2670-2677.
23. Pootrakul, P., Breuer, W., Sametband, M., Sirankapracha, P., Hershko, C. and Cabantchik, Z. I. (2004) Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood, 104, pp. 1504-1510.
24. Hebbel, R. P. (1985) Auto-oxidation and a membrane-associated 'Fenton reagent': A possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol, 14, pp. 129-140.
25. Lan, C Le, Loreal, O., Cohen, T., Ropert, M., Glickstein, H. and Laine, F. (2005) Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood, 105, pp. 4527-4531.
26. Hershko, C. and Peto, T. E. (1987) Non-transferrin plasma iron. Br J Haematol, 66, pp. 149-151.
27. Link, G., Pinson, A. and Hershko, C. (1985) Heart cells in culture: A model of myocardial iron overload and chelation. J Lab Clin Med, 106, pp. 147-153.
28. Cortelezzi, A., Cattaneo, C., Cristiani, S., Duca, L., Sarina, B. and Deliliers, G. L. (2000) Non-transferrin-bound iron in myelodysplastic syndromes: A marker of ineffective erythropoiesis?. Hematol J, 1, pp. 153-158.
29. Olivieri, N. F. and Brittenham, G. M. (1997) Iron-chelating therapy and the treatment of thalassemia. Blood, 89, pp. 739-761.
30. Olivieri, N. F., Nathan, D. G., MacMillan, J. H., Wayne, A. S., Liu, P. P. and McGee, A. (1994) Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med, 331, pp. 574-578.
31. Brittenham, G. M., Griffith, P. M., Nienhuis, A. W., McLaren, C. E., Young, N. S. and Tucker, E. E. (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med, 331, pp. 567-573.
32. Wolfe, L., Olivieri, N., Sallan, D., Colan, S., Rose, V. and Propper, R. (1985) Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med, 312, pp. 1600-1603.
33. Iancu, T C NH and Landing, B. H. (1977) The liver in thalassemia major: ultra-structural observations. Iron Metab Ciba Foundation Symp, 51, pp. 293-307.
34. Thakerngpol, K., Fucharoen, S., Boonyaphipat, P., Srisook, K., Sahaphong, S. and Vathanophas, V. (1996) Liver injury due to iron overload in thalassemia: Histopathologic and ultrastructural studies. Biometals, 9, pp. 177-183.
35. Gamberini, M. R., Fortini, M., De Sanctis, V., Gilli, G. and Testa, M. R. (2004) Diabetes mellitus and impaired glucose tolerance in thalassaemia major: Incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr Endocrinol Rev, 2, pp. 285-291.
36. Niederau, C., Fischer, R., Sonnenberg, A., Stremmel, W., Trampisch, H. J. and Strohmeyer, G. (1985) Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med, 313, pp. 1256-1262.
37. Wojcik, J. P., Speechley, M. R., Kertesz, A. E., Chakrabarti, S. and Adams, P. C. (2002) Natural history of C282Y homozygotes for hemochromatosis. Can J Gastroenterol, 16, pp. 297-302.
38. Olivieri, N. F., Brittenham, G. M., Matsui, D., Berkovitch, M., Blendis, L. M. and Cameron, R. G. (1995) Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med, 332, pp. 918-922.
39. Brittenham, G. M., Sheth, S., Allen, C. J. and Farrell, D. E. (2001) Non-invasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Semin Hematol, 38, pp. 37-56.
40. Fischer, R., Longo, F., Nielsen, P., Engelhardt, R., Hider, R. C. and Piga, A. (2003) Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: Application of SQUID biomagnetic liver susceptometry. Br J Haematol, 121, pp. 938-948.
41. St. Pierre, T. G., Clark, P. R., Chua-anusorn, W., Fleming, A. J., Jeffrey, G. P. and Olynyk, J. K. (2005) Non-invasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood, 105, pp. 855-861.
42. Anderson, L. J., Holden, S., Davis, B., Prescott, E., Charrier, C. C. and Bunce, N. H. (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J, 22, pp. 2171-2179.
43. Robins-Browne, R. M. and Prpic, J. K. (1985) Effects of iron and desferrioxamine on infections with Yersinia enterocolitica. Infect Immun, 47, pp. 774-779.
44. Ribes, J. A., Vanover-Sams, C. L. and Baker, D. J. (2000) Zygomycetes in human disease. Clin Microbiol Rev, 13, pp. 236-301.
45. Olivieri, N. F., Koren, G., Hermann, C., Bentur, Y., Chung, D. and Klein, J. (1990) Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet, 336, pp. 1275-1279.
46. Cohen, A. R., Galanello, R., Piga, A., De Sanctis, V. and Tricta, F. (2003) Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood, 102, pp. 1583-1587.
47. Daar, S. and Pathare, A. V. (2006) Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol, 85, pp. 315-319.
48. Tanner, M. A., Galanello, R., Dessi, C., Smith, G. C., Westwood, M. A. and Agus, A. (2007) A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation, 115, pp. 1876-1884.
49. Pennell, D. J., Berdoukas, V., Karagiorga, M., Ladis, V., Piga, A. and Aessopos, A. (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood, 107, pp. 3738-3744.
50. Borgna-Pignatti, C., Cappellini, M. D., De Stefano, P., Vecchio, G C Del, Forni, G. L. and Gamberini, M. R. (2006) Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood, 107, pp. 3733-3737.
51. Cohen, A. R. (2006) New advances in iron chelation therapy. Hematol Am Soc Hematol Educ Program, pp. 42-47.
52. Cappellini, M. D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S. and Agaoglu, L. (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 107, pp. 3455-3462.
53. Armand, P., Kim, H. T., Cutler, C. S., Ho, V. T., Koreth, J. and Alyea, E. P. (2007) Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood, 109, pp. 4586-4588.
54. Takatoku, T. U., Okamoto, S., Kanakura, Y., Sawada, K., Tomonaga, M. and Nakao, S. (2006) Retrospective survey of Japanese patients with transfusion-dependent myelodysplastic syndromes and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Blood, p. 108.
55. Jensen, P. D., Heickendorff, L., Pedersen, B., Bendix-Hansen, K., Jensen, F. T. and Christensen, T. (1996) The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol, 94, pp. 288-299.
56. Leitch, H., Goodman, T. A., Wong, K., Vickars, L., Galbraith, P. and Leger, C. (2006) Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy. Blood, p. 108.
57. Greenberg, P. L., Baer, M. R., Bennett, J. M., Bloomfield, C. D., De Castro, C. M. and Deeg, H. J. (2006) Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw, 4, pp. 58-77.
58. Thuret, CB-S, Bachir, D., Hacini, M., Pegourie-Bandelier, B., Gardembas-Pain, M. and (Intr. by Renaud Capdeville) (2006) Patient characteristics, quality-of-life and compliance with deferoxamine in patients with transfusional iron overload: Results of ISOSFER Study. Blood, p. 1085513.
59. Brun-Strang, C BD, De Montalembert, M. and Thuret, I. (2006) Socio-economic impact of infused iron chelation therapy in France: ISOSFER Study results. Blood, p. 1083354.
60. Delea, T. E., Sofrygin, O., Thomas, S. K., Baladi, J. F., Phatak, P. D. and Coates, T. D. (2007) Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics, 25, pp. 329-342.
61. Nisbet-Brown, E., Olivieri, N. F., Giardina, P. J., Grady, R. W., Neufeld, E. J. and Sechaud, R. (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet, 361, pp. 1597-1602.
62. Piga, A., Galanello, R., Forni, G. L., Cappellini, M. D., Origa, R. and Zappu, A. (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 91, pp. 873-880.